You are here:

paliperidone palmitate (Xeplion)

Advice

following a resubmission:

paliperidone palmitate prolonged release suspension for injection (Xeplion) is accepted  for use within NHS Scotland.

Indication under review: maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone.  In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, it may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.

Paliperidone prolonged release suspension for injection was non-inferior to another atypical antipsychotic depot injection in terms of control of schizophrenia symptoms over a 3-month period and was more effective than placebo in preventing relapse of schizophrenia.

Drug Details

Drug Name: paliperidone palmitate (Xeplion)
SMC Drug ID: 713/11
Manufacturer: Janssen-Cilag Ltd
Indication: For maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone. In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, it may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.
BNF Category:
Sub Category: 4.2 Drugs used in psychoses and related disorders
Submission Type: Resubmission
Status: Accepted
Date Advice Published: 7 November 2011

Archived Advice

Full submission 11 July 2011

Back